FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213885093> ?p ?o ?g. }

• W3213885093 endingPage "A895" @default.
• W3213885093 startingPage "A895" @default.
• W3213885093 abstract "Background SGN-B7H4V is a novel, investigational vedotin antibody drug conjugate (ADC) directed to B7-H4, a member of the B7 family of immune checkpoint ligands. B7-H4 expression is elevated on a variety of solid tumors including breast, ovarian, and endometrial tumors. 1 SGN-B7H4V is composed of a fully human IgG1 anti-B7-H4 monoclonal antibody (mAb) conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide linker. SGN-B7H4V is designed to bind and internalize the immune checkpoint ligand B7-H4/ADC complex from the surface of malignant cells and release the cytotoxic payload MMAE. This ”vedotin” drug linker system has been clinically validated by multiple ADC programs, including brentuximab vedotin, enfortumab vedotin, and polatuzumab vedotin. 2–4 Here, we characterize the target antigen B7-H4 and evaluate SGN-B7H4V activity in preclinical models. Methods B7-H4 expression was characterized by RNA expression and immunohistochemistry across multiple solid tumor types. The ability of SGN-B7H4V to kill B7-H4-expressing tumor cells in vitro and in vivo in a variety of xenograft tumor models was also evaluated. Finally, the tolerability of SGN-B7H4V was assessed in rodent and non-human primate toxicology studies. Results Immunohistochemistry confirmed expression of B7-H4 across multiple solid tumor types, including ovarian and breast tumors. In vitro, upon binding to SGN-B7H4V, the immune checkpoint ligand B7-H4 was rapidly internalized and delivered the cytotoxic payload MMAE. Moreover, SGN-B7H4V killed B7-H4-expressing tumor cells in vitro by MMAE-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). In vivo, SGN-B7H4V demonstrated strong anti-tumor activity in multiple xenograft models, including ovarian and breast cancer models. Activity was observed in models with both uniformly high and heterogeneous expression of B7-H4, consistent with robust bystander activity of vedotin ADCs. Finally, SGN-B7H4V was tolerated in both rat and non-human primate (NHP) toxicology studies at doses consistent with approved vedotin ADCs. Conclusions B7-H4 is a promising ADC target expressed by several solid tumor types. SGN-B7H4V demonstrates robust anti-tumor activity in preclinical models through multiple potential mechanisms and is tolerated in rat and NHP toxicity studies. Altogether, these data support further evaluation of SGN-B7H4V in a planned, first-in-human phase 1 clinical study. Acknowledgements We would like to thank Kellie Spahr for conjugation support and Martha Anderson for in vivo biology support. References Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, et al . An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm 2015; 12 (6):1717–29. Epub 2015/04/09. doi: 10.1021/mp5007745. PubMed PMID: 25853436. Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al . Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019; 37 (29):2592–600. Epub 2019/07/30. doi: 10.1200/JCO.19.01140. PubMed PMID: 31356140; PubMed Central PMCID: PMC. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30 (7):631–7. Epub 2012/07/12. doi: 10.1038/nbt.2289. PubMed PMID: 22781692. Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, et al . Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol 2019; 20 (7):998–1010. Epub 2019/05/19. doi: 10.1016/S1470-2045(19)30091–9. PubMed PMID: 31101489. Ethics Approval All animal studies were conducted in accordance with protocols reviewed and approved by the Institutional Animal Care and Use Committee at Seagen or the external testing facility that conducted the studies." @default.
• W3213885093 created "2021-11-22" @default.
• W3213885093 creator A5002326187 @default.
• W3213885093 creator A5006615047 @default.
• W3213885093 creator A5011408825 @default.
• W3213885093 creator A5017378932 @default.
• W3213885093 creator A5019036090 @default.
• W3213885093 creator A5021344389 @default.
• W3213885093 creator A5029132704 @default.
• W3213885093 creator A5046867683 @default.
• W3213885093 creator A5052020419 @default.
• W3213885093 creator A5053597932 @default.
• W3213885093 creator A5063894752 @default.
• W3213885093 creator A5064276812 @default.
• W3213885093 creator A5065579271 @default.
• W3213885093 creator A5068006242 @default.
• W3213885093 creator A5076787926 @default.
• W3213885093 creator A5078996982 @default.
• W3213885093 creator A5079575989 @default.
• W3213885093 creator A5086343549 @default.
• W3213885093 creator A5009419839 @default.
• W3213885093 date "2021-11-01" @default.
• W3213885093 modified "2023-10-14" @default.
• W3213885093 title "854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models" @default.
• W3213885093 doi "https://doi.org/10.1136/jitc-2021-sitc2021.854" @default.
• W3213885093 hasPublicationYear "2021" @default.
• W3213885093 type Work @default.
• W3213885093 sameAs 3213885093 @default.
• W3213885093 citedByCount "2" @default.
• W3213885093 countsByYear W32138850932023 @default.
• W3213885093 crossrefType "journal-article" @default.
• W3213885093 hasAuthorship W3213885093A5002326187 @default.
• W3213885093 hasAuthorship W3213885093A5006615047 @default.
• W3213885093 hasAuthorship W3213885093A5009419839 @default.
• W3213885093 hasAuthorship W3213885093A5011408825 @default.
• W3213885093 hasAuthorship W3213885093A5017378932 @default.
• W3213885093 hasAuthorship W3213885093A5019036090 @default.
• W3213885093 hasAuthorship W3213885093A5021344389 @default.
• W3213885093 hasAuthorship W3213885093A5029132704 @default.
• W3213885093 hasAuthorship W3213885093A5046867683 @default.
• W3213885093 hasAuthorship W3213885093A5052020419 @default.
• W3213885093 hasAuthorship W3213885093A5053597932 @default.
• W3213885093 hasAuthorship W3213885093A5063894752 @default.
• W3213885093 hasAuthorship W3213885093A5064276812 @default.
• W3213885093 hasAuthorship W3213885093A5065579271 @default.
• W3213885093 hasAuthorship W3213885093A5068006242 @default.
• W3213885093 hasAuthorship W3213885093A5076787926 @default.
• W3213885093 hasAuthorship W3213885093A5078996982 @default.
• W3213885093 hasAuthorship W3213885093A5079575989 @default.
• W3213885093 hasAuthorship W3213885093A5086343549 @default.
• W3213885093 hasBestOaLocation W32138850931 @default.
• W3213885093 hasConcept C126322002 @default.
• W3213885093 hasConcept C154317977 @default.
• W3213885093 hasConcept C159654299 @default.
• W3213885093 hasConcept C185592680 @default.
• W3213885093 hasConcept C202751555 @default.
• W3213885093 hasConcept C203014093 @default.
• W3213885093 hasConcept C204232928 @default.
• W3213885093 hasConcept C2777325958 @default.
• W3213885093 hasConcept C2777701055 @default.
• W3213885093 hasConcept C2778191690 @default.
• W3213885093 hasConcept C2780851360 @default.
• W3213885093 hasConcept C502942594 @default.
• W3213885093 hasConcept C542903549 @default.
• W3213885093 hasConcept C55493867 @default.
• W3213885093 hasConcept C70905583 @default.
• W3213885093 hasConcept C71924100 @default.
• W3213885093 hasConcept C8891405 @default.
• W3213885093 hasConcept C98274493 @default.
• W3213885093 hasConceptScore W3213885093C126322002 @default.
• W3213885093 hasConceptScore W3213885093C154317977 @default.
• W3213885093 hasConceptScore W3213885093C159654299 @default.
• W3213885093 hasConceptScore W3213885093C185592680 @default.
• W3213885093 hasConceptScore W3213885093C202751555 @default.
• W3213885093 hasConceptScore W3213885093C203014093 @default.
• W3213885093 hasConceptScore W3213885093C204232928 @default.
• W3213885093 hasConceptScore W3213885093C2777325958 @default.
• W3213885093 hasConceptScore W3213885093C2777701055 @default.
• W3213885093 hasConceptScore W3213885093C2778191690 @default.
• W3213885093 hasConceptScore W3213885093C2780851360 @default.
• W3213885093 hasConceptScore W3213885093C502942594 @default.
• W3213885093 hasConceptScore W3213885093C542903549 @default.
• W3213885093 hasConceptScore W3213885093C55493867 @default.
• W3213885093 hasConceptScore W3213885093C70905583 @default.
• W3213885093 hasConceptScore W3213885093C71924100 @default.
• W3213885093 hasConceptScore W3213885093C8891405 @default.
• W3213885093 hasConceptScore W3213885093C98274493 @default.
• W3213885093 hasIssue "Suppl 2" @default.
• W3213885093 hasLocation W32138850931 @default.
• W3213885093 hasLocation W32138850932 @default.
• W3213885093 hasOpenAccess W3213885093 @default.
• W3213885093 hasPrimaryLocation W32138850931 @default.
• W3213885093 hasRelatedWork W2123042378 @default.
• W3213885093 hasRelatedWork W2363885141 @default.
• W3213885093 hasRelatedWork W2886039816 @default.
• W3213885093 hasRelatedWork W2984962695 @default.
• W3213885093 hasRelatedWork W3006273887 @default.
• W3213885093 hasRelatedWork W3115086337 @default.

• next